8-K: Acadia Healthcare Reports Solid Q4 2024 Results and Announces $300 Million Share Repurchase Program

Acadia Healthcare announces a 4.2% increase in revenue for Q4 2024, driven by growth in same-facility revenue and strategic bed expansion, alongside a new $300 million share repurchase authorization.

Summary

• Acadia Healthcare reported its Q4 2024 and full-year 2024 financial results.
• Q4 revenue reached $774.2 million, a 4.2% increase year-over-year.
• Same facility revenue increased by 4.7%, with a 3.2% rise in patient days and a 1.4% increase in revenue per patient day.
• Net income attributable to Acadia was $32.6 million, or $0.35 per diluted share.
• Adjusted income attributable to Acadia was $59.2 million, or $0.64 per diluted share.
• Adjusted EBITDA totaled $153.1 million, including adjustments for a professional liability reserve and facility closure impact.
• The company added 577 newly licensed beds in Q4, including 344 from newly constructed facilities.
• Acadia completed construction on approximately 1,300 new beds in 2024.
• Startup losses for new facilities in Q4 were $11.2 million.
• A new $300 million share repurchase authorization was announced.
• Acadia provided 2025 financial guidance, projecting revenue between $3.3 and $3.4 billion and adjusted EBITDA between $675 and $725 million.
• Adjusted earnings per diluted share for 2025 are expected to be between $2.50 and $2.80.
• The company anticipates adding 800 to 1,000 beds in 2025.
• For the three-year period beginning in 2026, Acadia targets 7% to 9% average annual revenue growth and 8% to 10% average annual adjusted EBITDA growth, with 600 to 800 new bed additions per year.

Sentiment

Score: 7

Explanation: The sentiment is positive due to solid revenue growth, strategic bed expansion, and a new share repurchase program. However, increased startup losses and adjustments to EBITDA temper the overall outlook.

Positives

• Revenue increased by 4.2% in Q4 2024, indicating growth in the business.
• Same facility revenue growth of 4.7% suggests strong organic performance.
• The addition of 577 newly licensed beds expands the company's capacity to serve more patients.
• The $300 million share repurchase program could boost shareholder value.
• The company has a strong financial position with $76.3 million in cash and cash equivalents and $226.5 million available under its revolving credit facility as of December 31, 2024.
• Acadia added one new comprehensive treatment center (CTC), extending the Company's market reach to 163 CTCs across 33 states, treating over 72,000 patients daily in this critical area of care.

Negatives

• Net income attributable to Acadia totaled $32.6 million, or $0.35 per diluted share.
• Adjusted EBITDA totaled $153.1 million, including a $14.3 million professional liability reserve adjustment related to years prior to 2024, and a $5.0 million impact related to the decision to close one facility during the fourth quarter.
• Startup losses related to new facilities incurred in the fourth quarter were $11.2 million.
• The company expects a year-over-year increase in startup losses of approximately $25 million, totaling approximately $50-$55 million in losses for the full year 2025 related to newly opened facilities.
• The company expects a year-over-year net decrease in Medicaid supplemental payments of approximately $10 to $15 million in the first quarter of 2025 compared to the first quarter of 2024.

Risks

• Potential difficulties in integrating acquired facilities or realizing the expected benefits of expansions and joint ventures.
• Possible reductions in payments received from government and commercial payors.
• The occurrence of patient incidents, governmental investigations, litigation, and adverse regulatory actions.
• The risk that Acadia may not generate sufficient cash from operations to service its debt.
• Potential disruptions to information technology systems or cybersecurity incidents.
• Operating difficulties, including disruptions to the U.S. economy and financial markets, reduced admissions, increased costs, and changes in competition.

Future Outlook

Acadia expects continued growth in 2025, with revenue projected between $3.3 and $3.4 billion and adjusted EBITDA between $675 and $725 million. For the three-year period beginning in 2026, Acadia targets 7% to 9% average annual revenue growth and 8% to 10% average annual adjusted EBITDA growth, with 600 to 800 new bed additions per year.

Management Comments

• Chris Hunter, Chief Executive Officer of Acadia, remarked, Our fourth quarter financial and operating results capped off a year of solid growth and progress for Acadia.
• He also stated that the results reflect the robust demand for their behavioral healthcare services and their ability to expand capacity.
• Hunter noted that 2024 was their largest bed expansion year in Acadia history.
• He added that they are well-positioned for continued success with their expanding scale and diverse service lines.

Industry Context

Acadia's results reflect the strong demand for behavioral healthcare services in the U.S. The company's expansion strategy, including bed additions and joint ventures, positions it to capitalize on this growing market. As the largest stand-alone behavioral healthcare company in the U.S., Acadia is a key player in addressing a critical societal need.

Comparison to Industry Standards

• Acadia's revenue growth of 4.2% in Q4 2024 is comparable to other companies in the behavioral healthcare sector, such as Universal Health Services (UHS) and HCA Healthcare, which also experienced growth in their behavioral health segments.
• The company's focus on bed expansion aligns with the industry trend of increasing capacity to meet the rising demand for mental health services.
• Acadia's adjusted EBITDA margin of approximately 19.8% ($153.1 million/$774.2 million) is within the typical range for behavioral healthcare providers.
• The share repurchase program is a common strategy among publicly traded healthcare companies to return value to shareholders, similar to programs implemented by UHS and Community Health Systems (CYH).

Stakeholder Impact

• Shareholders may benefit from the share repurchase program and potential stock price appreciation.
• Employees will continue to be part of a growing organization with opportunities for advancement.
• Patients will have increased access to behavioral healthcare services through the company's bed expansion.
• The company's growth and expansion will likely have a positive impact on the communities it serves.

Next Steps

• Acadia will hold a conference call on February 28, 2025, to discuss the fourth quarter financial results.
• The company will continue to execute its growth strategy, including bed additions and joint ventures.
• Acadia will make share repurchases under the newly authorized program, subject to market conditions.

Key Dates

Keywords

Acadia Healthcare, Behavioral Healthcare, Financial Results, Share Repurchase, Bed Expansion, Revenue, EBITDA, Guidance